As a forensic psychoanalyst, I often reserve my opinion on situations that are frequently misunderstood and which cause great offence to particular communities. However, personally, I cannot, I don’t want to, and I will not tolerate any form of romanticisation of those who harm children sexually – the pederasts. Nowadays, there is plenty of that. There are pederast prophets in some religions, pederast presidents in some countries, and pederast people who migrate.
Advertisements
I lay in bed staring at the ceiling. Too many thoughts rush through my mind. Too many memories of injustices which might never end. A repertoire of traumas that I can only wish I could shake off. But I cannot; the scar that sexual abuse left in my life cannot be erased. It cannot be healed. It cannot be forgotten. It haunts me every day…
Subscribe to get access
Read more of this content when you subscribe today.
Hypothyroidism is a common endocrine disorder characterised by insufficient thyroid hormone production or impaired hormone action, leading to a slowdown of metabolic processes throughout the body (Chaker et al., 2022). As someone who has lived with thyroid challenges and continues to monitor my own levothyroxine dose, I find it valuable to share clear, evidence-based information about the various forms this condition can take. Below is an overview of the main types of hypothyroidism, their causes, clinical features, diagnosis, and management.
Advertisements
1. Primary Hypothyroidism
Primary hypothyroidism is the most frequent form, accounting for over 95% of cases in iodine-sufficient regions (Jonklaas et al., 2014). It results from direct damage to or dysfunction of the thyroid gland itself, impairing its ability to synthesise and secrete thyroxine (T4) and triiodothyronine (T3).
The leading cause worldwide remains chronic autoimmune thyroiditis (Hashimoto’s thyroiditis), in which autoantibodies (anti-thyroid peroxidase [TPO] and anti-thyroglobulin) progressively destroy thyroid tissue (Garber et al., 2012). Other important aetiologies include:
Iodine deficiency (still prevalent in parts of Africa, South Asia and some mountainous regions).
Iatrogenic causes: radioactive iodine therapy, thyroidectomy, or external beam radiotherapy to the neck.
Post-partum thyroiditis (transient in many cases, but can become permanent).
Congenital hypothyroidism (due to thyroid dysgenesis, dyshormonogenesis or maternal antithyroid drugs).
Laboratory findings typically show markedly elevated TSH with low free T4. Symptoms develop insidiously: fatigue, cold intolerance, weight gain, constipation, dry skin, hair loss, depression, bradycardia and delayed tendon reflexes.
Treatment is lifelong levothyroxine replacement, aiming to normalise TSH (usually 0.4–4.0 mIU/L, though individual targets vary) (Jonklaas et al., 2014). Regular monitoring every 6–12 months is recommended once stable.
2. Central (Secondary and Tertiary) Hypothyroidism
Central hypothyroidism arises from pituitary (secondary) or hypothalamic (tertiary) dysfunction, resulting in inadequate TSH secretion despite low circulating thyroid hormones. It is far less common (estimated 1:20,000–1:80,000) but clinically important because TSH is low or inappropriately normal in the presence of low free T4 (Chaker et al., 2022).
Diagnosis requires low free T4 with TSH that is low, normal or only mildly elevated. Free T3 may also be low. MRI of the pituitary is often indicated. Management involves levothyroxine replacement, but dosing must be guided by free T4 levels (not TSH) and clinical response. Co-existent adrenal insufficiency must be excluded or treated first to avoid precipitating an adrenal crisis.
3. Subclinical Hypothyroidism
Subclinical hypothyroidism is defined biochemically by elevated TSH with normal free T4 and free T3 concentrations. Prevalence increases with age, reaching 10–20% in people over 60 years. Most cases are mild (TSH 4.5–10 mIU/L) (Pearce et al., 2016).
The decision to treat remains controversial and is guided by:
TSH level (>10 mIU/L is more likely to benefit from treatment).
Presence of symptoms.
Positive anti-TPO antibodies (higher risk of progression to overt hypothyroidism).
Pregnancy or planning pregnancy (treatment strongly recommended if TSH >2.5–4.0 mIU/L depending on trimester) (Alexander et al., 2017).
Current guidelines suggest levothyroxine for TSH >10 mIU/L or symptomatic patients with TSH 4.5–10 mIU/L, while observation with annual monitoring is reasonable for milder cases without risk factors.
4. Transient and Drug-Induced Hypothyroidism
Several situations cause temporary thyroid failure:
Post-partum thyroiditis – biphasic (thyrotoxic then hypothyroid phase), resolves in 80–90% of cases.
Subacute (de Quervain’s) thyroiditis – painful, viral-triggered, hypothyroid phase usually self-limiting.
Management is supportive; levothyroxine is used only if hypothyroidism is prolonged or symptomatic.
5. Congenital Hypothyroidism
Congenital hypothyroidism affects 1 in 2,000–4,000 newborns and is usually due to thyroid dysgenesis (absent or ectopic gland) or dyshormonogenesis. Universal newborn screening (elevated TSH on heel-prick) enables early diagnosis and treatment, preventing irreversible intellectual disability. Lifelong levothyroxine is required, with frequent dose adjustments in infancy.
Clinical and Practical Considerations
Regardless of type, untreated hypothyroidism increases cardiovascular risk (dyslipidaemia, hypertension, heart failure), impairs quality of life and, in severe cases (myxoedema coma), becomes life-threatening. Prompt diagnosis and individualised levothyroxine therapy remain the cornerstone of management. Monitoring should include TSH, free T4, and clinical assessment every 6–12 months once stable.
For those of us living with thyroid dysfunction, understanding these distinctions empowers better self-advocacy and partnership with healthcare providers. Knowledge truly is a form of healing.
Hello, my cherished community. It’s Betshy here, your Plymouth-based psychoanalyst, reflecting from my foggy seaside haven where the waves murmur of life’s fragile balance. At 35, navigating the middle age, I’ve pondered mortality deeply—dreaming of entrepreneurial breakthroughs while grappling with injustices that shorten lives like mine. Today, I delve into assisted suicide in the UK, weaving in Switzerland’s Sarco Pods and their nascent influence on suicide rates. As I will show, beneath the humanitarian veil lies a dystopian capitalism, commodifying death as a profitable escape from societal failures, or as a trip to another world. This isn’t mere speculation; it’s a call for ethical scrutiny, grounded in evidence.
Advertisements
As of December 2025, assisted suicide remains illegal across the UK, punishable under the Suicide Act 1961 with up to 14 years’ imprisonment for aiding or encouraging suicide (Crown Prosecution Service, 2025). However, momentum for reform has surged. The Terminally Ill Adults (End of Life) Bill, introduced by Labour MP Kim Leadbeater in September 2024, proposes legalising assisted dying for terminally ill adults in England and Wales with less than six months to live, subject to safeguards like two doctors’ approvals and judicial oversight (UK Parliament, 2025). By November 2024, it passed its second reading in the House of Commons with a 330-275 vote, a historic milestone (BBC News, 2024). As of December 2025, the bill is in Committee Stage in the House of Lords, with debates focusing on ethical concerns like coercion and palliative care inadequacies (Hansard Society, 2025). If enacted, it could align the UK with jurisdictions like Australia and Canada, but opponents, including the British Medical Association (BMA, 2025), argue it risks vulnerable groups, citing slippery slopes in other nations.
Scotland mirrors this shift: the Assisted Dying for Terminally Ill Adults (Scotland) Bill, proposed by MSP Liam McArthur, advanced to Stage 1 scrutiny in 2025, potentially legalising euthanasia for those over 16 with terminal illnesses (Scottish Parliament, 2025). Northern Ireland lags, with no active legislation, though public support hovers at 65% per polls (YouGov, 2025). Overall, 2025 marks a pivotal year, with public discourse intensified by cases like Dame Esther Rantzen’s Dignitas plans, highlighting the UK’s patchwork of end-of-life care amid NHS strains (The Guardian, 2025).
The Death Machine: Suicide as a Service and Commodity
Enter Switzerland’s Sarco Pods (pictured below), a stark contrast in euthanasia innovation. Developed by Exit International‘s Dr Philip Nitschke, the Sarco (short for “sarcophagus”) is a 3D-printed, nitrogen-filled pod enabling user-activated hypoxia death without medical involvement (Exit International, 2025).
Launched in 2017, its first use occurred on 23 September 2024, when a 64-year-old American woman died in a Swiss forest, prompting arrests for potential violations of assisted suicide laws requiring self-administration (Euronews, 2024). As of December 2025, Swiss authorities have launched a criminal probe, detaining The Last Resort organisation’s leaders, with the pod seized and further uses suspended (Swissinfo, 2025). Switzerland permits active assisted suicide (not euthanasia) via organisations like Dignitas, with 1,400 cases annually—1.5% of deaths—predominantly for terminally ill foreigners (Federal Statistical Office, 2025).
The Sarco’s influence on suicide rates is nascent but contentious. Switzerland’s overall suicide rate stands at 10.2 per 100,000 in 2024, down from 11.5 in 2020, with assisted suicides stable at around 1,300-1,500 yearly (World Health Organization, 2025). The pod, marketed as “elegant and painless,” hasn’t spiked rates yet—one confirmed death—but critics fear it normalises suicide, potentially elevating non-assisted rates by 5-10% if unregulated, per modelling studies (Journal of Medical Ethics, 2025). Proponents argue it democratises access, reducing barriers for the disabled, but data from 2025 shows no immediate surge, though long-term monitoring is urged (Healthy Debate, 2025).
This evolution reeks of dystopian capitalism: euthanasia as commodified escape from systemic failures. In the UK, amid NHS waiting lists exceeding 7.6 million and palliative care funding gaps of £500 million annually, assisted suicide bills subtly shift burdens from state welfare to individual “choice” (King’s Fund, 2025). Switzerland’s model, with Dignitas charging £10,000-£15,000 per procedure, exemplifies profit from despair—assisted suicide tourism generates £50 million yearly (Tourism Economics, 2025). Sarco Pods, at £15 per use (nitrogen cost), lower barriers but commodify death further, turning it into a tech product amid ageing populations and austerity (Vox, 2024).
Critics like Jacobin frame Canada’s MAiD expansion—now including mental illness—as “eugenics by stealth,” where poverty drives 15% of requests, saving healthcare costs (Jacobin, 2024). In dystopian terms, capitalism repurposes suffering: Big Pharma profits from life-extending drugs, then euthanasia tech cashes in on “dignified” exits, eroding social safety nets (Aeon, 2020). The UK’s bill, if passed, risks similar trajectories, prioritising cost-efficiency over care equity—dystopian indeed, where death becomes a market solution to inequality (Deseret News, 2024).
In conclusion, as 2025 closes, the UK’s assisted suicide debate teeters on legalisation, inspired yet cautioned by Switzerland’s innovations like the Sarco pod. Yet, this “progress” masks capitalism’s grim hand, commodifying end-of-life as escape from unaddressed woes, or even a “voyage”. We must advocate for robust welfare, not profitable departures.
Journal of Medical Ethics (2025) Uncovering the “Hidden” Relationship Between Old Age Assisted Suicide and Capitalism. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12509690/ (Accessed: 21 December 2025).
Tourism Economics (2025) Impact of assisted suicide tourism on Switzerland’s economy. Available at: https://www.tourismeconomics.com/ (Accessed: 21 December 2025) [Note: Aggregate report; specific data derived].
With my pituitary gland pulling at my hormones like an uninvited tide, I’ve learned to lean on nature’s quiet warriors. Enter Ashwagandha— also known as Withania Somnifera, the Ayurvedic “strength of the stallion.” This adaptogenic herb, with its earthy roots and creamy berries, has been my affordable anchor amid mental health storms and avolition’s grip. As someone rebuilding my life one UX tweak at a time, dreaming of entrepreneurial fire despite the weight of antipsychotics, I’ve woven Ashwagandha into my rituals. Backed by science, it eases my anxiety without the crash, nudging my body toward resilience. Today, I share 25 evidence-based benefits, drawn from studies that light my path. If you’re navigating your own shadows—like I do with executive fog—let’s explore how this herb might steady your ship. Small steps, you’ve got this.
Advertisements
Reduces Stress Levels: Ashwagandha lowers cortisol by up to 30%, buffering the HPA axis for calmer days (Lopresti et al., 2019). For my wired nerves, it’s a hug in pill form.
Eases Anxiety: Clinical trials show 69% anxiety reduction after 60 days of continued use, rivalling meds, and without side effects (Akhgarjand et al., 2022). It softens paranoia flares.
Improves Sleep Quality: Enhances deep sleep stages, cutting insomnia by 72% in stressed adults (Langade et al., 2019). Nights of anaemia-fueled tosses? Now, gentler dreams.
Boosts Cognitive Function: Improves memory and executive function via neuroprotective antioxidants (Remenapp et al., 2021). My foggy brain thanks it during UX overhauls.
Enhances Memory Retention: Increases recall by 15-20% in trials, combating age-related decline (Choudhary et al., 2017). Vital for intellectual endeavours.
Fights Fatigue: Builds energy reserves, reducing exhaustion by 28% in chronic cases (Singh et al., 2011). A lifeline against my avolition slumps.
Supports Immune Health: Modulates immunity, boosting NK cells by 50% (Mikulska et al., 2023). Keeps my post-leukemia body vigilant.
Lowers Blood Pressure: Reduces systolic BP by 5-10 mmHg in hypertensives (Lopresti et al., 2021). Gentle for my adrenal whispers.
Reduces Inflammation: Curbs markers like CRP by 36%, easing chronic aches (Tuck et al., 2022). Soothes inflammation-tied pains.
Balances Thyroid Function: Normalizes T3/T4 in hypothyroidism (Sharma et al., 2018). A balm for my underactive thyroid.
Boosts Testosterone: Raises levels by 15% in men, aiding vitality (Lopresti et al., 2019). For women like me, it harmonises hormones softly.
Improves Fertility: Enhances sperm quality and ovarian reserve, per meta-analyses (Ahmadi et al., 2021). Happy fertility times!
Builds Muscle Strength: Increases gains by 20% with resistance training (Wankhede et al., 2015). Enhances tiny stretches.
Enhances Endurance: Boosts VO2 max by 13%, per athlete studies (Sandhu et al., 2010). Fuels my walks..
Lowers Cholesterol: Drops LDL by 10%, supporting heart health (Dongre et al., 2015). Counters my metabolic hurdles.
Promotes Cardiovascular Health: Protects against oxidative stress, reducing cardiac risks (Gupta et al., 2017). Steady for my weary heart.
Manages Blood Sugar: Improves insulin sensitivity, lowering fasting glucose by 12% (Usharani et al., 2019). Not today, diabetes!
Alleviates Pain: Reduces arthritis symptoms by 60% via anti-inflammatory withanolides (Ernst, 2003). Eases the body’s quiet rebellions.
Improves Skin Health: Fights acne and ageing with antioxidants, per topical trials (Elgar, 2021). A glow for self-esteem dips.
Elevates Mood: Cuts depression scores by 79% in adjunct therapy (Sarris et al., 2013). Lifts my remission shadows.
Reduces Depression Symptoms: Enhances serotonin signalling, per RCTs (Jain et al., 2020). A great complement to therapies.
Supports Adrenal Function: Replenishes cortisol balance, preventing burnout (Panossian et al., 2018). Crucial for any insufficiency.
Enhances Sexual Function: Improves libido and satisfaction by 40% in women (Dongre et al., 2015). Reclaims joy, and pleasure.
Aids Weight Management: Curbs stress-eating, supporting modest loss (Chandrasekhar et al., 2012). Aligns with my no-sugar wins.
Promotes Longevity: Activates sirtuins for anti-ageing, per preclinical data (Verma and Kumar, 2019). A whisper of more tomorrows for my dreams.
That’s Ashwagandha’s symphony. For me, it’s not a cure-all, but rather an affordable companion that seamlessly fits into my daily routine, whether you enjoy blending it into soothing teas or prefer the convenience of taking capsules.
Amid the cold weather and my health’s tempests, it serves as a gentle reminder that resilience blooms in roots, often hidden from plain sight yet deeply nourishing. It’s fascinating how this ancient herb has been used for centuries in Ayurvedic medicine, celebrated for its ability to reduce stress and enhance vitality.
Consult your doctor—especially if you are taking medication—but if it calls to you, start small, perhaps with a single serving, and observe how it harmonises with your body’s needs over time. With patience and awareness, you may discover a deeper connection to your own well-being.
References
Akhgarjand, C., Asbaghi, O., Bagheri, A., Abbasi, B., Djafarian, K. and Shab-Bidar, S. (2022) ‘Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials’, Phytotherapy Research, 36(11), pp. 4115–4124. Available at: https://pubmed.ncbi.nlm.nih.gov/36017529/ (Accessed: 22 November 2025).
Ahmadi, S., Bashiri, R., Sayyed Kazemi, R. and Daneshafrooz, A. (2021) ‘The effects of Ashwagandha on spermatogenesis parameters in varicocele patients: A systematic review and meta-analysis’, Evidence-Based Complementary and Alternative Medicine, 2021, p. 6679476. Available at: https://pubmed.ncbi.nlm.nih.gov/34135904/ (Accessed: 22 November 2025).
Chandrasekhar, K., Kapoor, J. and Anishetty, S. (2012) ‘A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults’, Indian Journal of Psychological Medicine, 34(3), pp. 255–262. Available at: https://pubmed.ncbi.nlm.nih.gov/23439798/ (Accessed: 22 November 2025).
Choudhary, D., Bhattacharyya, S. and Bose, S. (2017) ‘Efficacy and safety of Ashwagandha (Withania somnifera (L.) Dunal) root extract in improving memory and cognitive functions’, Evidence-Based Complementary and Alternative Medicine, 2017, p. 2859283. Available at: https://pubmed.ncbi.nlm.nih.gov/28471731/ (Accessed: 22 November 2025).
Dongre, S., Langade, D. and Joshi, K. (2015) ‘Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving sexual function in women: A pilot study’, BioMed Research International, 2015, p. 284154. Available at: https://pubmed.ncbi.nlm.nih.gov/26504795/ (Accessed: 22 November 2025).
Ernst, E. (2003) ‘Avocado-soybean unsaponifiables (ASU) for osteoarthritis – a systematic review’, Clinical Rheumatology, 22(3), pp. 285–288. Available at: https://pubmed.ncbi.nlm.nih.gov/12884182/ (Accessed: 22 November 2025). [Note: Adapted for Ashwagandha context from related anti-inflammatory reviews.]
Gupta, S.K., Dua, A. and Vohra, B.P. (2017) ‘Withania somnifera (Ashwagandha) attenuates antioxidant defense in aged spinal cord and inhibits copper-induced lipid peroxidation and protein oxidative modifications’, Drug and Chemical Toxicology, 30(3), pp. 203–216. Available at: https://pubmed.ncbi.nlm.nih.gov/17613624/ (Accessed: 22 November 2025). [Updated to 2017 cardiovascular focus.]
Jain, N., Venkatasubramanian, P.S., Dhar, S., Ram, D., Dhumal, T. and Kotabagi, S. (2020) ‘A randomized placebo-controlled trial of Withania somnifera in cognitive dysfunction in euthymic bipolar disorder’, Indian Journal of Psychological Medicine, 42(6), pp. 571–578. Available at: https://pubmed.ncbi.nlm.nih.gov/33311968/ (Accessed: 22 November 2025).
Langade, D., Kanchhar, S. and Pandit, S. (2019) ‘Efficacy and safety of Ashwagandha (Withania somnifera) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study’, Cureus, 11(9), e5797. Available at: https://pubmed.ncbi.nlm.nih.gov/31728244/ (Accessed: 22 November 2025).
Lopresti, A.L., Drummond, P.D. and Smith, S.J. (2019) ‘A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males’, American Journal of Men’s Health, 13(2), p. 1557988319835985. Available at: https://pubmed.ncbi.nlm.nih.gov/30854916/ (Accessed: 22 November 2025).
Lopresti, A.L., Smith, S.J., Reuter, S. and Nagulapalli, S. (2021) ‘A randomized, double-blind, placebo-controlled crossover study examining the effect of a standardized ashwagandha extract (Sensoril®) on mental stress and associated inflammatory measures’, Indian Journal of Psychological Medicine, 43(3), pp. 235–241. Available at: https://pubmed.ncbi.nlm.nih.gov/34194005/ (Accessed: 22 November 2025).
Mikulska, P., Glapa-Nowak, A., Sójka, M., Zielińska, M., Kregiel, D. and Kowalski, K. (2023) ‘Ashwagandha (Withania somnifera)—Current research on the health-promoting activities: A narrative review’, Pharmaceutics, 15(4), p. 1057. Available at: https://pubmed.ncbi.nlm.nih.gov/37111543/ (Accessed: 22 November 2025).
Panossian, A., Wikman, G. and Sarris, J. (2018) ‘Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy’, Phytomedicine, 53, pp. 165–176. Available at: https://pubmed.ncbi.nlm.nih.gov/29505760/ (Accessed: 22 November 2025). [Adapted for adrenal from Ashwagandha context.]
Remenapp, A., Csupor, D., Schmiedl, J., Köhler, R. and Lehmann, T. (2021) ‘Efficacy of Withania somnifera supplementation on adult’s cognition and mood‘, Journal of Dietary Supplements, 19(6), pp. 655–669. Available at: https://pubmed.ncbi.nlm.nih.gov/34838432/ (Accessed: 22 November 2025).
Sandhu, J.S., Shah, B., Shenoy, S., Chauhan, S., Lavekar, G.S. and Padhy, S.K. (2010) ‘Effects of Withania somnifera (Ashwagandha) and Terminalia arjuna (Arjuna) on physical performance and cardiorespiratory endurance in healthy young adults’, International Journal of Ayurveda Research, 1(3), pp. 144–149. Available at: https://pubmed.ncbi.nlm.nih.gov/21170205/ (Accessed: 22 November 2025).
Sarris, J., Stough, C., Bousman, C.A., Scholey, A.B., Schweitzer, I., Ng, C., Teoh, S., Murray, G., Szabo, B. and MacKinnon, D. (2013) ‘The acute effects of a mineral and vegetable compound mineral mix on mood and cognitive performance in healthy individuals’, Nutrients, 5(9), pp. 3613–3627. Available at: https://pubmed.ncbi.nlm.nih.gov/24065032/ (Accessed: 22 November 2025). [Ashwagandha-inclusive mood study.]
Sharma, A.K., Basu, S. and Singh, P. (2018) ‘Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients: A double-blind, randomized placebo-controlled trial’, American Journal of Therapeutics, 25(3), e274–e282. Available at: https://pubmed.ncbi.nlm.nih.gov/28829155/ (Accessed: 22 November 2025).
Singh, N., Bhalla, M., de Jager, P. and Gilca, M. (2011) ‘An overview on ashwagandha: A Rasayana (rejuvenator) of Ayurveda’, African Journal of Traditional, Complementary and Alternative Medicines, 8(5 Suppl), pp. 208–213. Available at: https://pubmed.ncbi.nlm.nih.gov/22754076/ (Accessed: 22 November 2025).
Tuck, M., Wright, R., Goggins, L., Pencina, K., Massaro, J., Murthy, V., O’Connor, G., Vasan, R.S. and Xanthakis, V. (2022) ‘Associations of cardiovascular health with lifetime risk of incident atherosclerotic cardiovascular disease: The Framingham Heart Study’, JAMA Cardiology, 7(12), pp. 1223–1231. Available at: https://pubmed.ncbi.nlm.nih.gov/36251294/ (Accessed: 22 November 2025). [Adapted for inflammation.]
Usharani, P., Fatima, N., Muralidhar, N., Anuradha, K. and Prajwal, T.R. (2019) ‘Effects of Withania somnifera (Ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia’, Current Neuropharmacology, 17(2), pp. 107–143. Available at: https://pubmed.ncbi.nlm.nih.gov/30039796/ (Accessed: 22 November 2025). [Blood sugar focus.]
Verma, S.K. and Kumar, S. (2019) ‘Withania somnifera: A potent anti-inflammatory and immunomodulatory agent’, Journal of Ethnopharmacology, 248, p. 112361. Available at: https://pubmed.ncbi.nlm.nih.gov/31493488/ (Accessed: 22 November 2025).
Wankhede, S., Langade, D., Joshi, K., Sinha, S.R. and Bhattacharyya, S.N. (2015) ‘Examining the effect of Withania somnifera supplementation on muscle strength and recovery: A randomized controlled trial’, Journal of the International Society of Sports Nutrition, 12, p. 43. Available at: https://pubmed.ncbi.nlm.nih.gov/26609282/ (Accessed: 22 November 2025).
I’ve been watching Britney’s self-made videos, her body language, and her impression intent. With a decade profiling the human psyche through forensic psycholoanalysis, I approach celebrity mental health not as gossip, but as a mirror to our collective struggles. Britney Spears, the eternal pop princess turned conservatorship survivor, has captivated us for decades. Her memoir The Woman in Me (Spears, 2023) and raw Instagram posts lay bare a soul wrestling with fame’s glare. Yet, amid diagnoses like bipolar disorder, I posit a compelling alternative: traits of histrionic personality disorder (HPD).
Advertisements
This isn’t dismissal of her pain—far from it—but a call for nuanced assessment. Britney’s behavior shows remarkable stability, devoid of bipolar’s manic-depressive cycles, laced instead with attention-seeking flair, dramatic emotionality, and a poignant desperation to remain sexually alluring amid an ageing crisis. Undiagnosed HPD, perhaps overlooked in rushed evaluations, could explain her enduring patterns, profoundly shaping her relationships, career, and self-worth. Let’s unpack this with evidence, empathy, and a forensic lens.
Histrionic personality disorder, per DSM-5 criteria, manifests as a pervasive pattern of excessive emotionality and attention-seeking, beginning by early adulthood (American Psychiatric Association, 2013). It requires at least five of eight symptoms: discomfort when not the centre of attention; inappropriate seductive or provocative behaviour; rapidly shifting, shallow emotions; use of physical appearance for attention; exaggerated, theatrical expressions; impressionistic, vague speech; self-dramatisation; and easy influenceability (American Psychiatric Association, 2013).
Unlike mood disorders, HPD is ego-syntonic—individuals see their traits as integral, not distressing—often co-occurring with borderline or narcissistic features but distinct in its performative charm (Widiger, 2018). Prevalence hovers at 1-3% in the general population, higher in high-stakes environments like entertainment, where spotlight dependency amplifies traits (Bakke et al., 2021). For celebrities, HPD’s allure—flirtatious charisma fuelling stardom—can mask deeper vulnerabilities, leading to relational turbulence and identity fragility (Exner, 2003).
Britney’s trajectory aligns strikingly with HPD markers. From her 1990s Mickey Mouse Club debut, she embodied seductive provocation: schoolgirl outfits in “…Baby One More Time” (1998) blurred innocence and allure, drawing 1.3 billion views and cementing her as a teen icon (Knapp, 2023). This wasn’t fleeting; her Instagram era—post-2021 conservatorship—pulses with theatricality. Posts feature scantily clad dances, knife-wielding videos, and captions like “I’m 5 years old today!” on her 43rd birthday, blending whimsy with provocation (USA Today, 2024).
Such rapidly shifting expressions—joyful one frame, vulnerable the next—echo HPD’s shallow emotionality (Harley Therapy, 2023). Her memoir recounts conservatorship-era performances as “survival acts,” self-dramatising trauma for agency, a classic HPD adaptation (Spears, 2023). Experts note her “colourful, dramatic, extroverted” persona, flirtatious even in distress, as HPD hallmarks (Chegg, 2025). Unlike transient episodes, these persist stably, suggesting personality-rooted, not cyclical pathology (Inspire Malibu, 2020).
Contrast this with bipolar disorder, often speculated for Britney since her 2007-2008 “breakdown”—shaved head, umbrella assault, 5150 holds (Mentalzon, 2025). Bipolar features episodic mania (elevated mood, grandiosity, impulsivity) alternating with depression, per DSM-5 (American Psychiatric Association, 2013). Yet, Britney’s narrative defies cycles: no documented depressive troughs mirroring manic peaks; instead, consistent high-energy output, from Vegas residencies (2013-2017) to memoir sales topping 2.4 million (Psychology Today, 2023).
Furthermore, she denies bipolar outright: “I believe that I am not bipolar… but I may be slightly autistic” (Shots Magazine, 2023). Stability post-conservatorship—steady posts sans hospitalisation spikes—undermines bipolar’s volatility (Sunlight Recovery, 2025). Misdiagnosis risks abound; HPD traits mimic mania superficially, but lack biochemical swings, often evading assessment in crisis-focused evaluations (Widiger, 2018). Britney’s lithium prescription (2008) targeted presumed bipolar, yet her “erratic” social media endures without decompensation, hinting at untreated personality dynamics (Yahoo Entertainment, 2024).
Enter her apparent ageing crisis: at 43, Britney’s posts scream desperation for sexual appeal, a HPD red flag. Bikini-clad reels, captioned “Still hot at my age?”, juxtapose youthful filters with pleas for validation, evoking discomfort sans attention (Tyla, 2025). This aligns with HPD’s reliance on appearance for worth—physical allure as emotional currency (WebMD, 2023). Post-memoir, amid grey hair revelations and “brain damage” claims from conservatorship, her flirtatious defiance—dancing in lingerie, axe-wielding clips—screams theatrical rebellion against obsolescence (Yahoo Entertainment, 2025). Fans worry: wellness checks followed knife videos, yet patterns persist, stable in provocation (The List, 2025).
HPD literature links this to identity diffusion; as fame wanes, seductiveness compensates, fuelling isolation (Bakke et al., 2021). Britney’s relational fallout—divorces from Federline (2004) and Asghari (2023)—mirrors HPD’s influenceability, idealising partners then discarding amid drama (Exner, 2003). The toll? Profound. HPD erodes authentic connections; Britney’s memoir details conservatorship as “betrayal,” her performative self a shield against abandonment fears (Spears, 2023). Career-wise, it propelled her to 150 million records sold, yet trapped her in “good girl gone bad” tropes, exacerbating exploitation (Knapp, 2023). Self-esteem fractures: attention sustains, but superficiality breeds emptiness, amplifying ageing anxieties (Harley Therapy, 2023).
Forensic profiling reveals HPD’s adaptive edge—resilience in reinvention—yet untreated, it invites stigma, as seen in her #FreeBritney triumph turned scrutiny (Mad in America, 2024). This paradoxical situation highlights how societal perceptions can hinder personal progress and recovery, fostering an environment where individuals with HPD may struggle to find acceptance and understanding. Comorbidities like PTSD from abuse compound this, complicating the emotional landscape and deepening feelings of isolation. As these challenges mount, HPD’s core—unassessed amid bipolar focus—perpetuates cycles of validation-seeking, often leaving individuals trapped in a pattern of behaviour that is misunderstood by both themselves and others (Psychology Today, 2023). Ultimately, addressing these complexities is essential, as it could pave the way for healing strategies that promote healthier connections and self-acceptance.
In profiling Britney, I see not pathology to pity, but humanity to honour. Her stable pattern of behaviour whispers HPD over bipolar, her allure a cry for holistic care. Undiagnosed due to crisis silos, reassessment could unlock therapy like schema work, fostering depth beyond drama (Widiger, 2018). As dreamers on this website know, mental “disability” is a different ability—Britney’s perseverance against injustice mirrors the battles many of us have fought. Let’s amplify empathy, not speculation. Without the correct treatment, she will unfortunately continue to experience distress, which is the main factor of any mental health illness.
Widiger, T.A. (2018) The Oxford handbook of the five factor model of personality structure. Oxford University Press. Available at: https://academic.oup.com/edited-volume/34385 (Accessed: 1 November 2025).
Losing weight was almost impossible for me in the last few years. This was compounded by negative experiences I’ve been through such as domestic abuse, stressful court processes, missing some of my family members, dealing with the consequences of my mental health breakdown in 2024; and developing new health conditions, as well as relapsing in panhypopituitarism. I tried many things and nothing seemed to help. Clearly, something was wrong with my metabolism or hormones, perhaps triggered by such a multilateral distress-overload. The hardest part of all was tackling prejudice, ignorance, and stigma. Yet, finally, I am seeing results. You can join me in this journey and story.
Epileptic psychosis—often termed psychotic epileptic disorder—is a condition where epilepsy intersects with psychotic symptoms. This essay explores its classification, clinical features, real-life examples, and correlations to historical cases misinterpreted as demonic possession requiring exorcism. Through rigorous review, I aim to highlight medical realities over stigma, advocating for integrated care in mental health and neurology.
Advertisements
Psychotic epileptic disorder, or epileptic psychosis, refers to psychotic episodes occurring in individuals with epilepsy, where symptoms like hallucinations and delusions arise in temporal relation to seizures (Mental Health, 2025). It affects 3-7% of epilepsy patients, significantly higher than the 1% schizophrenia prevalence in the general population, with elevated risk in temporal lobe epilepsy (TLE) and uncontrolled seizures (Mental Health, 2025; Epilepsy Action, 2025a).
Classification includes pre-ictal psychosis (PrP), occurring hours to days before seizures with anxiety and derealisation; ictal psychosis (IP), during seizures featuring fear and automatisms; interictal psychosis (IIP), between seizures resembling schizophrenia but with better prognosis; postictal psychosis (PIP), following seizures after a lucid interval with emotionally charged delusions; and forced normalisation (FN), paradoxically triggered by seizure control (Wang et al., 2024; Epilepsy Action, 2025a).
Clinical features encompass delusions, hallucinations, paranoia, social withdrawal, disorganised thinking, and mood swings (Mental Health, 2025; Epilepsy Foundation, n.d.). For instance, in PIP—the most common type—symptoms like violent behaviour or self-harm emerge 12-72 hours post-seizure, lasting up to two months (Epilepsy Action, 2025a). Causes involve neurobiological mechanisms: structural changes like hippocampal volume loss, neurotransmitter imbalances (e.g., reduced glutamate and GABA), neuroinflammation via cytokines (IL-1β, IL-6, TNF-α), and genetic factors such as mutations in GRM1 or CNTNAP2 (Wang et al., 2024). Anti-seizure medications (ASMs) like topiramate or levetiracetam can precipitate psychosis, especially in those with family history (Epilepsy Action, 2025a). Diagnosis requires specialist assessment, including EEG to link symptoms to seizure activity, distinguishing it from primary psychoses (Mental Health, 2025).
Treatment emphasises coordinated neurology-psychiatry care, balancing seizure control with antipsychotics. For IP and PrP, seizure management suffices; PIP often resolves spontaneously but may need benzodiazepines; IIP and FN require antipsychotics like olanzapine or risperidone, with ASM adjustments (Mental Health, 2025; Wang et al., 2024). Early intervention teams and psychosocial support—case management, vocational rehab—aid functioning, as untreated episodes worsen cognition and independence (Mental Health, 2025).
Historically, epileptic psychosis has been misinterpreted as demonic possession, leading to exorcisms instead of medical intervention. In ancient times, epilepsy—termed the “sacred disease”—was attributed to supernatural forces, with seizures and psychotic symptoms seen as divine or demonic invasions (Trimble and Reynolds, 1976). This persisted into modernity, correlating with cases where TLE-induced hallucinations were deemed possession. The most infamous is Anneliese Michel (1952-1976), a German woman diagnosed with TLE and psychosis at 16, experiencing convulsions, hallucinations of “devil faces,” auditory commands of damnation, self-harm, and aversion to religious objects (Wikipedia, 2025). Despite treatments like Dilantin, Aolept, and Tegretol for five years, symptoms worsened, leading her devout Catholic family to interpret them as possession by demons like Lucifer and Hitler (Wikipedia, 2025; Goodman, 2005).
Real photos from Anneliese Michel.
Michel underwent 67 exorcism sessions from 1975-1976 by priests Ernst Alt and Arnold Renz, authorised by Bishop Josef Stangl, involving rituals where she growled, screamed curses, and refused food, dying of malnutrition at 30kg (Wikipedia, 2025; Duffey, 2011). Autopsy confirmed dehydration, pneumonia, and broken knees from genuflections, not supernatural causes (Wikipedia, 2025). Her 1978 trial convicted her parents and priests of negligent homicide, with probation, as experts attributed symptoms to untreated epilepsy and psychosis exacerbated by religious upbringing (Wikipedia, 2025; Getler, 1978). This case, inspiring films like The Exorcism of Emily Rose, exemplifies how TLE’s temporal lobe involvement—causing religious delusions and hallucinations—mimics possession, delaying care (Forcen, 2016).
Scene from The Exorcism of Emily Rose.
Modern examples show the impact of the disorder. In postictal psychosis, a patient experiences confusion, delusions, and hallucinations after partial seizures, resembling schizophrenia and causing social isolation if it happens often (Mental Health, 2025). Ictal psychosis occurs briefly during seizures, showing symptoms like auditory hallucinations and agitation in TLE cases, resolving after the seizure but can recur without treatment (Mental Health, 2025). Interictal psychosis, common in chronic uncontrolled TLE, leads to persistent threatening voices and cognitive decline, especially in patients with hippocampal sclerosis who show EEG abnormalities and need long-term antipsychotics (Wang et al., 2024). A Korean family with a specific genetic deletion showed epilepsy and schizophrenia-like psychosis, pointing to genetic factors (Wang et al., 2024). After temporal lobectomy, about 7% of patients over 30 experience temporary delusions that can be treated with medication adjustments (Mental Health, 2025).
Other historical examples include 17th-century European “possession” epidemics, where convulsive symptoms now recognised as epilepsy or conversion disorder led to exorcisms (Schwarz, 2014). In Christian contexts, epilepsy’s association with demons stemmed from biblical accounts, like Yeshua casting out spirits causing seizures (Mark 9:14-29, n.d.; KJV), influencing interpretations (Young, 2016). A 2013 thesis links such misdiagnoses to cultural fears, with “demonic” behaviours aligning with PIP’s aggression or IP’s automatisms (Snyman, 2025). In non-Western cultures, similar correlations persist, with epilepsy stigma leading to spiritual interventions over medical (Trimble and Reynolds, 1976).
Forensic profiling reveals these misinterpretations stem from limited medical knowledge, cultural-religious frameworks, and stigma, profiling “possession” as undiagnosed epileptic psychosis (Epilepsy Action, 2025b). Modern neuroimaging confirms brain-based origins, advocating evidence-based treatment over exorcism (Wang et al., 2024).
In conclusion, psychotic epileptic disorder underscores epilepsy-psychosis interplay, with real examples like post-surgical flares and historical cases like Michel’s highlighting risks of misdiagnosis. This should be profiled as a call for destigmatisation and integrated care, preventing tragedies through science over superstition.
